Trending in Endocrinology: Hip BMD surrogate, EU denosumab and more
Автор: LucidQuest
Загружено: 2026-01-13
Просмотров: 3
Описание: Endocrinology highlights: FDA qualifies hip bone mineral density change as a fracture surrogate, promising shorter osteoporosis trials and fresh investment. Entera Bio advances oral long-acting PTH with single-dose, multi-day exposure in minipigs. Denosumab biosimilars from Celltrion and Samsung Bioepis expand across Europe, intensifying price competition. AI tongue imaging shows adjunctive potential for diabetes and gastric cancer screening. Genprex details GPX-002 gene therapy manufacturing plans. FDA grants Priority Review for Tzield in children 1–7. Medtronic secures pharmacy-benefit access for MiniMed 780G and new CGMs nationwide.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
